Arch Biopartners Inc. (TSX Venture: ARCH, OTCQB: ACHFF) closed a non-brokered private placement offering of 1,000,000 common shares at $0.60 per share for gross proceeds of $600,000 CAD, according to a company statement.

The proceeds will fund general working capital and operating expenses not covered by the company's human trial funding grants. The offering requires regulatory approvals, including final approval from the TSX Venture Exchange.

An officer of the company purchased 81,667 common shares as part of the offering, constituting a related party transaction under Multilateral Instrument 61-101. The transaction is exempt from formal valuation and minority shareholder approval requirements because the fair market value does not exceed 25% of the company's market capitalization.

All shares issued will be subject to a hold period of four months and one day from the April 2, 2026 closing date. No finders' fees were paid in connection with the offering.

Arch Biopartners develops treatments for acute kidney injury and chronic kidney disease. The company's development pipeline includes LSALT peptide in a Phase II trial targeting cardiac surgery-associated acute kidney injury, cilastatin in a Phase II trial targeting toxin-induced acute kidney injury, and a chronic kidney disease platform for next-generation therapeutics.

The company has 67,933,289 common shares outstanding following the transaction.